ASR-XL Metal-on-Metal 522 Post-Market Surveillance Study

NCT ID: NCT01884532

Last Updated: 2016-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

146 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-05-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical study is to evaluate blood metal ion levels as a function of time of implantation for the ASR-XL MoM system.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adverse Local Tissue Reaction Total Hip Arthroplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2 year post-op

Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 2 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.

ASR-XL Metal-on-Metal

Intervention Type DEVICE

All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.

3 year post-op

Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 3 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.

ASR-XL Metal-on-Metal

Intervention Type DEVICE

All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.

4 year post-op

Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 4 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.

ASR-XL Metal-on-Metal

Intervention Type DEVICE

All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.

5 year post-op

Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 5 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.

ASR-XL Metal-on-Metal

Intervention Type DEVICE

All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.

6 year post-op

Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 6 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.

ASR-XL Metal-on-Metal

Intervention Type DEVICE

All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ASR-XL Metal-on-Metal

All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ASR-XL ASR-XL MoM

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to (or capable of) provide written, voluntary consent to participate in the clinical investigation,
2. Is willing and able to return for all protocol defined clinic visits,
3. Subject has (or had, if previously revised) a combination of the following implants in the study hip:

1. ASR-XL cup or ASR 300 cup
2. XL femoral head
3. ASR-XL tapered sleeve adapter
4. One of the following stems

i. S-ROM ii. Corail iii. Tri-Lock iv. AML v. Summit vi. Prodigy vii. C-Stem AMT
4. Subject has high quality films available for review that were taken within 12 months of primary surgery of the following views:

1. Standing AP-Pelvis
2. Standing AP-Proximal Femur (if this view is not available but the AP-Pelvis shows the entire implant and greater trochanter, that is also acceptable)
3. Lauenstien Lateral Proximal Femur (Lateral-femur).

Exclusion Criteria

1. The subject refuses to allow their medical records to be inspected by the Sponsor, representatives of the Sponsor, the medical office staff and/or representatives from the FDA
2. The implanted hip components in the study hip (exclusive of cement), are not all DePuy components
3. The femoral component is the ASR hemi or some other hemi device.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

DePuy Orthopaedics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mary F Panozzo, BS

Role: STUDY_DIRECTOR

DePuy Synthes Joint Reconstruction

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fort Collins, Colorado, United States

Site Status

Glenview, Illinois, United States

Site Status

Rockford, Illinois, United States

Site Status

Las Vegas, Nevada, United States

Site Status

Durham, North Carolina, United States

Site Status

Cincinnatti, Ohio, United States

Site Status

Austin, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.